Skip to main content
OpenTrials
Completed

NCT Number: NCT04764435

The Effect of Physician Ownership on Dialysis Outcomes

Many dialysis facilities have financial relationships with nephrologists, including joint venture agreements, where the nephrologist owns a minority share of the dialysis facility. Such agreements could present a conflict of interest with respect to patient care. This study will investigate whether these joint venture agreements are associated with differences in the quality of care provided by dialysis facilities.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Dialysis Financial Disclosure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The investigators will use the United States Renal Data System (USRDS), a registry of all patients on dialysis in the US irrespective of payer. The dataset includes patient characteristics (biologic and sociodemographic) within 45 days of initiating dialysis for all patients with ESKD irrespective of insurance coverage, death data for all patients with ESKD irrespective of insurance, dialysis facility characteristics, which are updated annually, longitudinal treatment data submitted by the end-stage renal disease (ESRD) networks for all patients irrespective of insurance, and CROWNWeb clinical data: monthly treatment data (e.g., Kt/V, treatment time, serum hemoglobin, vascular access) submitted by dialysis facilities for all patients irrespective of insurance. The registry is linked to Fee-for-service Medicare claims for all patients with this payer. All data have already been collected (i.e., this is a retrospective study) and deidentified by a data distributor.

The investigators have also obtained a cross-sectional dataset of dialysis facilities and physician owners in 2017 from the Centers for Medicare & Medicaid Services (CMS) through a Freedom of Information Act request.

In this study, the investigators will link the USRDS to this cross-sectional dataset. The investigators will also link the data to publicly available data from Dialysis Facility Compare (which contains quality performance of each dialysis facility, published by the government on a quarterly basis) and Census data (which contains geographic sociodemographic characteristics).

From this data linkage, the investigators will study differences between facilities that are physician owned and those that are not physician owned. The investigators will study outcomes both at the facility level and the patient level.

All models will have an alpha of 5% and will have 2-sided statistical tests.

For facility level outcomes:

The investigators will construct a facility level dataset and compare physician-owned facilities to non-physician owned facilities adjusting for facility characteristics and regional (zipcode level) sociodemographic characteristics. The investigators will also test the effect of incorporating patient characteristics into the model. For patient characteristics, the investigators will take the average for each facility's population (e.g., average age, % of patients male, etc.). The investigators will use ordinary least squares for continuous outcomes and logistic regression for binary outcomes. The investigators will use robust standard errors.

For patient level outcomes:

The investigators will construct a patient-month panel dataset and compare patients dialyzing at physician-owned facilities to those dialyzing at non-physician owned facilities. The investigators will adjust for patient, facility, and zipcode level sociodemographic characteristics. Since all outcomes are binary, the investigators will use logistic regression for all models. The investigators' primary analysis will be logistic regression, adjusting for patient, facility, zipcode characteristics, with patient-level fixed effects and non-parametric bootstrap standard errors. In order, The investigators will explore the sensitivity of results to the following:

  • logistic regression with all adjusters, patient-level fixed effects, and robust standard errors
  • ordinary least squares with all adjusters, patient-level fixed effects, cluster-robust standard errors at the facility level
  • ordinary least squares with all adjusters, patient-level fixed effects, robust standard errors

The investigators also pre-specify the adjusters below:

Patient characteristics (comorbidities will be obtained using the Chronic Conditions Warehouse software on a 12 month lookback of Medicare fee-for-service claims)

  • Age
  • Sex
  • Race
  • Ethnicity
  • Prior transplant
  • Incident patient (first 120 days of dialysis)
  • Years with ESRD
  • Dual Eligibility
  • Hypertension
  • Alzheimers
  • Atrial fibrilation
  • Prior myocardial infarction
  • Asthma
  • Breast Cancer
  • Cataract
  • Chronic obstructive pulmonary disease
  • Colorectal Cancer
  • Depression
  • Diabetes
  • Endometrial Cancer
  • Glaucoma
  • Congestive Heart Failure
  • Hip Fracture
  • Hyperlipidemia
  • Hypertension
  • Ischemic heart disease
  • Lung cancer
  • Osteoporosis
  • Prostate Cancer
  • Rheumatoid Arthritis / Osteoarthritis
  • Prior stroke / transient ischemic attack
  • Benign prostatic hyperplasia

Facility characteristics

  • For-profit status
  • Chain owned
  • Number of patients at facility
  • Patient:staff ratio
  • ESRD Network

Regional (zipcode level) sociodemographic characteristics

  • Median Income
  • % of zipcode with high school degree
  • % of zipcode below poverty line

We pre-specify a subgroup analysis by whether the dialysis facility is owned by a large dialysis organization (i.e., Davita, Fresenius).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult
  • Receiving dialysis for ESRD in the US
  • Medicare fee for service as primary payer (and had Medicare FFS for at least 12 months prior to the month
  • Received dialysis between 1/1/2017-12/31/2017
  • Receiving dialysis in a free-standing facility
  • No missing data

Exclusion criteria

  • Pediatric (< 18 years)
  • Receiving dialysis in hospital-based facility
  • Receiving dialysis in a facility that had >= 15% pediatric patient months

Treatment and study plan

Physician ownership

Other

The "intervention" or exposure is whether the dialysis facility was owned by a physician in 2017

Large dialysis organization ownership

Other

The "intervention" or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017

Primary outcomes

  1. Facility level outcome: Facility 5-star rating

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Whether a facility was a "high-quality" facility using the Dialysis Facility Compare aggregate score in 2017. The variable will be dichotomized into:

    • High-quality: 4-5 stars
    • Low-quality: 1-3 stars

  2. Facility level outcome: % of patient-months with long-term catheter

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient used a catheter for 3 months or longer in 2017

  3. Facility level outcome: % of patient-months with hemoglobin < 10 g/dL

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a hemoglobin < 10

  4. Facility level outcome: % of patient-months with hemoglobin > 12 g/dL

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a hemoglobin > 12

  5. Facility level outcome: % of patient-months with serum calcium > 10.2 mg/dL

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a serum calcium > 10.2

  6. Facility level outcome: % of patient-months with serum phosphate > 7 mg/dL

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a serum phosphate > 7

  7. Facility level outcome: % of patient-months with Kt/V >= 1.2 (for hemodialysis)

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a Kt/V >= 1.2 (hemodialysis only)

  8. Facility level outcome: % of patient-months with Kt/V >= 1.7 (for peritoneal dialysis)

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient had a Kt/V >= 1.7 (peritoneal dialysis only)

  9. Facility level outcome: standardized mortality rate

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Facility's standardized mortality rate according to Dialysis Facility Compare

  10. Facility level outcome: standardized hospitalization rate

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Facility's standardized hospitalization rate according to Dialysis Facility Compare

  11. Facility level outcome: standardized 30-day readmission rate

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Facility's standardized 30-day readmission rate according to Dialysis Facility Compare

  12. Facility level outcome: standardized infection ratio

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Facility's standardized infection ratio according to Dialysis Facility Compare

  13. Facility level outcome: standardized transfusion rate

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    Facility's standardized transfusion rate according to Dialysis Facility Compare

  14. Facility level outcome: % of patient months where fistula is being used (hemodialysis)

    Time frame: Cross-sectional from October 2017 dataset (aggregates quality performance from the calendar year 2016)

    The fraction of patient-months of a dialysis facility where the patient was using a fistula (hemodialysis only)

  15. Patient level outcome: mortality

    Time frame: For each calendar month in 2017, determine whether the patient was alive or dead (administrative data indicate the exact date of death)

    Assess the exact date of death (reported in the administrative dataset)

  16. Patient level outcome: home dialysis (peritoneal dialysis or home hemodialysis)

    Time frame: For each calendar month in 2017, determine whether the patient used home dialysis for the plurality of that month (claims indicate type of dialysis for each calendar day of the month)

    Using claims data (granular at a daily level), determine the dialysis modality used for the plurality of that month

  17. Patient level outcome: serum hemoglobin < 10 g/dL

    Time frame: For each calendar month in 2017, determine whether the patient's serum hemoglobin was < 10 at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    Whether the patient's serum hemoglobin < 10 at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  18. Patient level outcome: serum hemoglobin > 12 g/dL

    Time frame: For each calendar month in 2017, determine whether the patient's serum hemoglobin was > 12 at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    Whether the patient's serum hemoglobin was > 12 at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  19. Patient level outcome: serum calcium > 10.2 mg/dL

    Time frame: For each calendar month in 2017, determine whether the patient's serum calcium > 10.2 at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)h and year

    Whether the patient's serum calcium was > 10.2 at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  20. Patient level outcome: serum phosphate > 7 mg/dL

    Time frame: For each calendar month in 2017, determine whether the patient's serum phosphate was > 7 at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    Whether the patient's serum phopshate was > 7 at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  21. Patient level outcome: hospitalization in that month

    Time frame: For each calendar month in 2017, determine whether the patient experienced a hospitalization (claims data provide a daily assessment of whether patient was hospitalized)

    Whether the patient had a hospitalization in a given month, using claims data (claims are granular at a daily level)

  22. Patient level outcome: 30-day readmission following a discharge in that month

    Time frame: For each calendar month in 2017, determine whether the patient experienced a hospitalization that was later followed by a 30-day readmission (claims data provide a daily assessment of whether patient was hospitalized)

    Whether the patient had a discharge in a given month that was followed by a 30-day readmission, using claims data (claims are granular at a daily level)

  23. Patient level outcome: unplanned 30-day readmission following a discharge in that month

    Time frame: For each calendar month in 2017, determine whether the patient experienced a hospitalization that was later followed by an unplanned 30-day readmission (claims data provide a daily assessment of whether patient was hospitalized)

    Whether the patient had a discharge in a given month that was followed by an unplanned 30-day readmission, using claims data (claims are granular at a daily level)

  24. Patient level outcome: using a fistula in that month (hemodialysis)

    Time frame: For each calendar month in 2017, determine whether the patient was using a fistula at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    Whether a fistula was used at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  25. Patient level outcome: using a catheter in that month (hemodialysis)

    Time frame: For each calendar month in 2017, determine whether the patient was using a dialysis catheter at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    Whether a dialysis catheter was used at the end of a given month, using CROWNWeb data (reported at the end of each calendar month)

  26. Patient level outcome: using a catheter for 3 or more months

    Time frame: For each calendar month in 2017, determine whether the patient was using a fistula at the end of the calendar month, and at the end of the previous two months (dialysis facilities report to CROWNWeb at the end of each month)

    Whether a dialysis catheter was used at the end of a given month and at the end of the previous 2 calendar months, using CROWNWeb data (reported at the end of each calendar month)

  27. Patient level outcome: using an erythropoietin stimulating agent

    Time frame: For each calendar month in 2017, determine whether the patient was using an erythropoietin stimulating agent at the end of the calendar month (dialysis facilities report to CROWNWeb at the end of each month)

    The type of erythropoietin stimulating agent in a given month and the total dose administered, using CROWNWeb data (reported at the end of each calendar month)

  28. Patient level outcome: receipt of a blood transfusion

    Time frame: For each calendar month in 2017, determine whether the patient received a blood transfusion in the calendar month (claims data report on a daily basis when a patient received a blood transfusion)

    Whether the patient received a blood transfusion in a given month, using claims data (granular at a daily level)

  29. Patient level outcome: dose of erythropoietin stimulating agent

    Time frame: For each calendar month in 2017, determine the type of erythropoietin stimulating agent used for that month and the total dose (dialysis facilities report to CROWNWeb at the end of each month)

    The type of erythropoietin stimulating agent in a given month and the total dose administered, using CROWNWeb data (reported at the end of each calendar month)

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • University of Pennsylvania

Registry information

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Feb 21, 2021
Registry last updated
Mar 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.